Evidence shows that NaB could promote glucagon-like peptide-1 (GLP-1) secretion from the intestinal L cells 12
Njalsson, R., Ristoff, E., Carlsson, K., Winkler, A., Larsson, A
GLP-1 receptor agonist therapy represents one of the most significant advances in medical weight loss and metabolic optimization, not because it's a quick fix, but because it works by addressing the underlying biological drivers of weight gain, appetite dysregulation, and cardiometabolic disease
But I was surprised to see dysaesthesiawhich manifests as skin sensitivity/tingling/burning/neuropathic painreported in 22.9% at 7.2 mg vs 6.0% at 2.4 mg and 0.5% with placebo
The safest approach is one where ingredient selection is guided by your specific health context, documented deficiencies or risk factors, and clear informed consent not by trends or social media influence alone